Scarica l'app Stockscreener
293.13
0.97%
-2.87
Dopo l'orario di chiusura:
293.21
0.08
+0.03%
Precedente Chiudi:
$296.00
Aprire:
$289.13
Volume 24 ore:
304.16K
Relative Volume:
0.62
Capitalizzazione di mercato:
$11.51B
Reddito:
$1.16B
Utile/perdita netta:
$34.55M
Rapporto P/E:
340.85
EPS:
0.86
Flusso di cassa netto:
$134.18M
1 W Prestazione:
-1.41%
1M Prestazione:
+11.76%
6M Prestazione:
+26.14%
1 anno Prestazione:
+40.56%
Intervallo 1D:
$289.00
$296.48
Intervallo di 1 settimana:
$288.28
$301.15
Portata 52W:
$148.00
$310.00
Penumbra Inc Stock (PEN) Company Profile
Nome
Penumbra Inc
Settore
Industria
Telefono
(510) 995-2486
Indirizzo
ONE PENUMBRA PLACE, ALAMEDA, CA
Confronta PEN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
293.13 | 11.51B | 1.16B | 34.55M | 134.18M | 0.86 |
|
ABT
Abbott Laboratories
|
132.60 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.24 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
381.36 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.45 | 107.01B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.11 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-14 | Iniziato | BofA Securities | Buy |
| 2025-01-21 | Iniziato | UBS | Buy |
| 2024-12-17 | Iniziato | Oppenheimer | Outperform |
| 2024-12-11 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-09-18 | Iniziato | Stifel | Buy |
| 2024-09-03 | Iniziato | Leerink Partners | Outperform |
| 2024-07-31 | Downgrade | Citigroup | Buy → Neutral |
| 2024-07-31 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-02-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-09-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-29 | Downgrade | Needham | Buy → Hold |
| 2023-01-30 | Iniziato | Piper Sandler | Overweight |
| 2022-11-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-10-05 | Downgrade | Citigroup | Buy → Neutral |
| 2022-09-09 | Aggiornamento | Needham | Hold → Buy |
| 2022-07-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-04-19 | Iniziato | Deutsche Bank | Buy |
| 2022-03-08 | Iniziato | Needham | Hold |
| 2021-09-16 | Iniziato | Truist | Buy |
| 2021-06-04 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-12-16 | Downgrade | BTIG Research | Buy → Neutral |
| 2020-10-07 | Ripresa | Canaccord Genuity | Buy |
| 2020-09-29 | Iniziato | BTIG Research | Buy |
| 2020-09-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-05-30 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-05-21 | Iniziato | William Blair | Outperform |
| 2018-10-29 | Ripresa | BofA/Merrill | Buy |
| 2018-10-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-02-21 | Iniziato | William Blair | Outperform |
| 2018-01-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2015-11-30 | Reiterato | Canaccord Genuity | Buy |
| 2015-10-13 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Penumbra Inc Borsa (PEN) Ultime notizie
LAWSUIT FILED: Penumbra, Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton LLP - ACCESS Newswire
SHAREHOLDER ALERT: Penumbra, Inc. Investigated for Possible Securities Laws Violations by Block & Leviton LLP; Investors Should Contact the Firm - ACCESS Newswire
Penumbra Inc.: Can Its Innovation & Product Pipeline Foster Long-Term Growth & Competitiveness? - Smartkarma
Penumbra, Inc. Reports First Quarter 2025 Financial Results - Eastern Progress
We Think You Can Look Beyond Penumbra's (NYSE:PEN) Lackluster Earnings - simplywall.st
Penumbra, Inc. to Present at the BofA Securities 2025 Health Car - GuruFocus
Exclusive: Penumbra Management Team Set for Key Presentation at BofA Healthcare Conference - Stock Titan
Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference - Longview News-Journal
Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
3 Reasons Growth Investors Will Love Penumbra (PEN) - Yahoo Finance
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Ischemic Neurological Interventional Medical Devices Market - openPR.com
Penumbra projects 12%-14% revenue growth for 2025 amid strong thrombectomy performance - MSN
Penumbra, Inc. (NYSE:PEN) Q1 2025 Earnings Call Transcript - Insider Monkey
Earnings Beat: Penumbra, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - simplywall.st
Penumbra, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - Yahoo Finance
Penumbra EVP Roberts sells shares worth $180,006 By Investing.com - Investing.com Canada
Penumbra Inc. Earnings Call Highlights Strong U.S. Growth - TipRanks
Penumbra EVP Roberts sells shares worth $180,006 - Investing.com
Abstract 160: Utilization of Penumbra MIDWAY 43 Catheter in Complex Neurovascular Interventions: Case Study Analysis - American Heart Association Journals
Stifel raises Penumbra stock price target to $318 - Investing.com Australia
Penumbra Reaches Analyst Target Price - Nasdaq
Penumbra First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst - Benzinga
Penumbra Inc (PEN) Trading 6.02% Higher on Apr 24 - GuruFocus
UBS raises Penumbra stock price target to $330, maintains Buy rating - Investing.com
Stifel raises Penumbra stock price target to $318 By Investing.com - Investing.com South Africa
Penumbra Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Expand - Yahoo Finance
UBS Adjusts Price Target on Penumbra to $330 From $320, Maintains Buy Rating - marketscreener.com
Truist Boosts Penumbra (PEN) Price Target Following Strong Q1 Pe - GuruFocus
Truist Boosts Penumbra (PEN) Price Target Following Strong Q1 Performance | PEN Stock News - GuruFocus
BTIG raises Penumbra stock price target to $320 from $305 By Investing.com - Investing.com South Africa
UBS Increases Price Target for Penumbra (PEN) to $330 | PEN Stoc - GuruFocus
Penumbra (PEN) Target Price Raised to $330 by RBC Capital | PEN Stock News - GuruFocus
Penumbra (PEN) Price Target Raised by Stifel Analyst Following S - GuruFocus
Penumbra (PEN) Sees Price Target Increase to $320 by BTIG | PEN Stock News - GuruFocus
Penumbra (PEN) Sees Price Target Increase Following Strong Q1 Pe - GuruFocus
Penumbra (PEN) Sees Price Target Increase Following Strong Q1 Performance | PEN Stock News - GuruFocus
BTIG raises Penumbra stock price target to $320 from $305 - Investing.com
Penumbra revenue increases 16.3% to USD 324.1M in Q1 2025 - Medical Buyer
Earnings call transcript: Penumbra beats Q1 2025 forecasts, stock surges By Investing.com - Investing.com Canada
Penumbra: Q1 Earnings Snapshot - MySA
Penumbra Inc earnings beat by $0.16, revenue topped estimates - Investing.com India
Penumbra Inc (PEN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst International ... - Yahoo Finance
Earnings call transcript: Penumbra beats Q1 2025 forecasts, stock surges - Investing.com
Penumbra Inc (PEN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst International Challenges - GuruFocus
Decoding Penumbra Inc (PEN): A Strategic SWOT Insight - GuruFocus
Penumbra Inc Azioni (PEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
11.62%
0.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):